For more information, s. Varicella Vaccine ACIP Recommendations. Preparations The vaccine includes an attenuated strain of varicella wild and traces of gelatin and neomycin. It is as a single antigen vaccine or as a combined preparation with MMR (MMRV) available. Indications The varicella vaccine is a routine childhood vaccination (see Table: Recommended vaccination schedule for the age of 0-6 years). The varicella vaccine with a single antigen is recommended for all persons aged ? 13 years who have no evidence of immunity to varicella The reference to immunity consists of the following aspects: documentation of two doses of the varicella vaccine, which at a distance were administered by ? 4 weeks history of varicella or herpes zoster, which is confirmed by a doctor laboratory confirmation of protective levels of varicella antibodies birth in the US before 1980, with the exception of health workers, pregnant women and people with immunosuppressive conditions the vaccine is recommended especially for people who do not have evidence of immunity and varicella are likely to be exposed to or transfer; including the following persons shall be: health workers household contacts of immunocompromised persons persons who work in places where exposure or transmission is likely (eg, teachers, students, educators, residents and employees of institutional facilities, inmates and staff of correctional institutions, military personnel. ) women of childbearing age who are not pregnant adolescents and adults living in households with children International travelers a following the exposure vaccination with varicella vaccine with a single antibody is recommended for children without evidence of immunity and should adults without evidence immunity offered. The vaccine is effective in preventing or relieving the disease, when administered within 3 days and possibly up to 5 days after exposure. The vaccine should be administered as soon as possible. If exposure to varicella does not lead to an infection, the vaccine should provide protection from exposure to the following exposures, even if the vaccine is given> 5 days after exposure. Varicella-zoster immunoglobulin (see table: Available in the US immunoglobulins and antitoxins *) is recommended for post-exposure prophylaxis in individuals who have no evidence of immunity, are at increased risk for severe varicella and / or have contraindications to the varicella vaccine , These people Immunocompromised people are without evidence of immunity Pregnant women without evidence of immunity Infants whose mothers develop chickenpox within 5 days before to 2 after childbirth Hospitalized premature infants who were born at 28 weeks of gestation and whose mothers do not proof immunity to varicella have Hospitalized preterm infants born before 28 weeks of gestation or at birth ? 1000 grams weigh, regardless of whether their mothers evidence of immunity to varicella have contraindications and precautions include the following contraindications: a severe allergic reaction ( z., anaphylaxis) after a previous dose or heavy to a vaccine component Known primary or acquired immunodeficiency (eg. B. due to leukemia; lymphoma; solid tumors; Tumors that affect the bone marrow or lymphatic system; AIDS; severe HIV infection; Treatment with chemotherapy; or long-term use of immunosuppressants) If people are not as immunocompetent known 1st degree that have a congenital hereditary immunodeficiency Confirmed or suspected pregnancy The varicella vaccine with a single antigen can children aged 1 to 8 years old, HIV a infection have to be given if their CD4 percentage ? 15%; he can be given persons aged> 8 years when their CD4 cell count is ? 200 ul. The precautions include Moderate or severe acute illness with or without fever (vaccination, if possible, be postponed until the disease is over) Recent (within 11 months) treatment with blood products contain antibodies (specific interval depends on the product) Use specific antiviral drugs: d. H. Acyclovir, famciclovir or valacyclovir (these drugs, if possible, stopped 24 hours prior to vaccination and not resumed for 14 days after vaccination) Breastfeeding is not a contraindication for vaccination. Breastfeeding women who do not have evidence of immunity, can be vaccinated after birth and continue breastfeeding. Dosage and Administration The dose is 0.5 ml and s.c. given in two doses: the aged 12 – 15 months and aged 4 – 6 years. If children, adolescents or adults, only one dose has been given a catch-up dose is recommended. The recommended minimum distance between the first dose and the second catch-up dose is 3 months for children aged ? 12 years and 4 weeks for persons aged ? 13 years; the second dose can be given at any distance which is longer than the minimum. When adults believe that they did not have chickenpox or that they are likely to be exposed to chicken pox or they could transfer, the number of protective antibodies should be measured to check for evidence of immunity and thus to determine the need for vaccination. Immunoglobulins, especially varicella zoster immunoglobulin should not be given 5 months ago 2 months after vaccination, since immunoglobulins can prevent the formation of protective antibodies. Candidate children with HIV infection 2 doses of the varicella vaccine given with a single antigen at intervals of 3 months. Because impaired cellular immunity increases the risk of complications after vaccination with a live vaccine, these children should be encouraged to come back for an evaluation if they develop a varicella-like rash after vaccination. A prenatal evaluation of women at Hiweise on varicella immunity is indicated. to be born before 1980, is not considered proof of immunity for pregnant women. After the completion or termination of pregnancy should women who have no evidence of immunity who received the first dose of vaccine before discharge and the second dose 4 to 8 weeks later, usually during a visit after delivery. Women should be advised to avoid pregnancy for 1 month after each dose. Side effects Most side effects are minimal and include temporary pain, tenderness and redness at the injection site. On occasion, 1 to 3% of vaccinated subjects within 1 month after vaccination to a weak makulopapulären or varizellenähnlichen rash. Vaccinated people who develop this rash should avoid contact with immunocompromised people conscientiously until disappearance. The spread of the virus from vaccinees to susceptible contacts is rare but can cause serious problems, including pneumonia, hepatitis, severe rash and shingles with meningitis. However, such problems rarely develop. Because a Reye’s syndrome could develop, patients should avoid <16 years salicylates for 6 weeks after vaccination.